CosIng Checker
CosIng Checker
EU cosmetic ingredients, restrictions and safety
Login
Official EU label nameGlossary entry 556

ACETAMINOPHEN

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 0 of 13 indexed market datasets: 0 country records and 0 EU Annex records. Every result and evidence gap is listed below.

0 markets with evidence
Markets checked
13
Markets with evidence
0
Evidence gaps
13
Resolved identifiers
2

A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.

Resolved substance identity

CAS:103-90-2
EC:203-157-5
Ingredient index records:
ACETAMINOPHEN
Ph. Eur. name: paracetamolum
Cosmetic functions: SKIN CONDITIONING

Acetamide, N-(4-hydroxyphenyl)-

Open full local profile
3 matched or reported names
ACETAMINOPHENparacetamolparacetamolum

Regulatory evidence in all 13 markets

Open each matched record for its scope, concentration, conditions, warnings and official source version.

Swipe or scroll horizontally to see dataset coverage and next actions.

MarketResultRecordsDatasetMeaning / next action
European Union
EU
No local match0
Complete annex dataset
Regulation (EC) 1223/2009 consolidated to 1 May 2026
No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain
GB
No local match0
Complete consolidated annex dataset
GB retained Regulation 1223/2009 schedules, effective 15 August 2026
No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.
Canada
CA
No local match0
Complete Hotlist snapshot
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025
The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.
New Zealand
NZ
No local match0
Complete schedules dataset
Cosmetic Products Group Standard schedules effective 1 January 2026
The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
ASEAN
ASEAN
No local match0
Complete regional annex dataset
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
China
CN
No local match0
Complete prohibited catalogues plus official-source workflow
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025
IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately.
Japan
JP
No local match0
Complete Standards appendices dataset
MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot
The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion.
South Korea
KR
No local match0
Complete current appendix dataset
MFDS Notice 2026-19, effective 18 March 2026
Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
United States
US
No local match0
Complete enumerated federal ingredient rules
eCFR Title 21 issue date 27 August 2026
FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia
AU
No local match0
Complete cosmetic-relevant Poisons Standard subset plus official workflow
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026
An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil
BR
No local match0
Complete prohibited dataset plus current restricted-list workflow
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
India
IN
No local match0
Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)
The standards are separate controlled publications; absence from a locally indexed excerpt is not permission.
Saudi Arabia
SA
No local match0
Complete official list index
SFDA live prohibited/restricted lists, snapshot 30 August 2026
No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.
No market rows match this filter.

Chemical identity and properties

PubChem 2D chemical structure for CAS 103-90-2
CAS 103-90-2PubChem CID 1983

Acetaminophen

IUPAC name
N-(4-hydroxyphenyl)acetamide
Molecular formula
C8H9NO2
Molecular weight
151.16 g/mol
Exact mass
151.063328530 Da
XLogP3
0.5
Topological polar surface area
49.3 Ų
Hydrogen-bond donors
2
Hydrogen-bond acceptors
2
Covalent units
1
Defined stereocentres
0

Also known as

Paracetamol4-AcetamidophenolTylenolAPAP4'-HydroxyacetanilideDatrilPanadolN-Acetyl-p-aminophenol
16 more reported names
AcetaminofenAlgotropylp-Acetamidophenolp-HydroxyacetanilideDolipraneAcamolAnelixLonaridNaprinolAbensanilAcetagesicAcetalginAlvedonAnaflonApamideClixodyne
Open full PubChem recordPubChem annotations3D structure image
External database identifiers

Evidence from additional scientific databases

EMBL-EBI ChEBI
Exact identifier matchCHEBI:46195

paracetamol

A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

Formula
C8H9NO2
Average mass
151.165 g/mol
Monoisotopic mass
151.06333 Da
Formal charge
0
  • phenols — is a (CHEBI:33853)
  • acetamides — is a (CHEBI:22160)
  • cyclooxygenase 2 inhibitor — has role (CHEBI:50629)
  • cyclooxygenase 1 inhibitor — has role (CHEBI:50630)
  • non-narcotic analgesic — has role (CHEBI:35481)
  • antipyretic — has role (CHEBI:35493)
  • non-steroidal anti-inflammatory drug — has role (CHEBI:35475)
  • anti-HBV agent — has role (CHEBI:64951)
  • anti-HIV agent — has role (CHEBI:64946)
  • antibacterial agent — has role (CHEBI:33282)
  • xenobiotic — has role (CHEBI:35703)
  • hepatotoxic agent — has role (CHEBI:50908)
  • human blood serum metabolite — has role (CHEBI:85234)
  • cyclooxygenase 3 inhibitor — has role (CHEBI:73263)
  • environmental contaminant — has role (CHEBI:78298)
  • geroprotector — has role (CHEBI:176497)
  • ferroptosis inducer — has role (CHEBI:173085)
  • analgesic — has role (CHEBI:35480)
  • 4-aminophenol — has functional parent (CHEBI:17602)
  • cyclooxygenase 2 inhibitor — has role (CHEBI:50629)
  • cyclooxygenase 1 inhibitor — has role (CHEBI:50630)
  • non-narcotic analgesic — has role (CHEBI:35481)
  • antipyretic — has role (CHEBI:35493)
  • non-steroidal anti-inflammatory drug — has role (CHEBI:35475)
  • anti-HBV agent — has role (CHEBI:64951)
  • anti-HIV agent — has role (CHEBI:64946)
  • antibacterial agent — has role (CHEBI:33282)
  • xenobiotic — has role (CHEBI:35703)
  • hepatotoxic agent — has role (CHEBI:50908)
  • human blood serum metabolite — has role (CHEBI:85234)
  • cyclooxygenase 3 inhibitor — has role (CHEBI:73263)
  • environmental contaminant — has role (CHEBI:78298)
  • geroprotector — has role (CHEBI:176497)
  • ferroptosis inducer — has role (CHEBI:173085)
  • analgesic — has role (CHEBI:35480)
  • anxiolytic drug — has role (CHEBI:35474)
  • anti-arrhythmia drug — has role (CHEBI:38070)
  • antirheumatic drug — has role (CHEBI:35842)
  • antineoplastic agent — has role (CHEBI:35610)
  • neuroprotective agent — has role (CHEBI:63726)
  • hypoglycemic agent — has role (CHEBI:35526)
  • antiglaucoma drug — has role (CHEBI:39456)
Additional curated names
N-(4-hydroxyphenyl)acetamide4-acetamidophenol4-(Acetylamino)phenol4'-hydroxyacetanilideAcenolAcetaminofenacetaminofenacetaminophenAcetaminophenacetaminopheneAPAPEfferalganN-acetyl-p-aminophenolp-acetamidophenolp-acetaminophenolp-hydroxyacetanilidep-hydroxyphenolacetamideNSC-109028NSC-3991p-AcetylaminophenolParacetamolP-hydroxy-acetanilid
Cross-references from this source
  • CAS: 103-90-2 — ChemIDplus
  • CAS: 103-90-2 — KEGG COMPOUND
  • CAS: 103-90-2 — NIST Chemistry WebBook
  • MANUAL_X_REF: 1906 — ChemSpider
  • MANUAL_X_REF: 52 — DrugCentral
  • MANUAL_X_REF: Acetaminophen — Wikipedia
  • MANUAL_X_REF: C06804 — KEGG COMPOUND
  • MANUAL_X_REF: CPD-7669 — MetaCyc
  • MANUAL_X_REF: D00217 — KEGG DRUG
  • MANUAL_X_REF: DB00316 — DrugBank
  • MANUAL_X_REF: HMDB0001859 — HMDB
  • MANUAL_X_REF: LSM-5533 — LINCS
  • MANUAL_X_REF: TYL — PDBeChem
  • REGISTRY_NUMBER: 2208089 — Beilstein
  • REGISTRY_NUMBER: 2208089 — Reaxys

Mapped by: Exact CAS cross-reference in the ChEBI compound record. Source updated: 2026-08-29. Retrieved: 2026-08-31. Open source record

NIH PubChem PUG-View
Exact identifier match1983

Attributed physical-property, hazard, environmental and use annotations.

  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) shou Source: CAMEO Chemicals
  • Note: This chemical does not meet GHS hazard criteria for 1.2% (5 of 432) of reports. Source: European Chemicals Agency (ECHA)
  • Signal: Warning Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (98.1%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (17.4%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (17.1%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H412 (36.8%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P264, P264+P265, P270, P273, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 432 reports by companies from 47 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 5 of 432 reports by companies.; There are 45 notifications provided by 427 of 432 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H401: Toxic to aquatic life [Hazardous to the aquatic environment, acute hazard]; H411: Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Source: NITE-CMC
  • Precautionary Statement Codes: P273, P391, and P501 (click each P-code to see the statement) Source: NITE-CMC
  • Signal: Danger Source: NITE-CMC
  • GHS Hazard Statements: H341: Suspected of causing genetic defects [Warning Germ cell mutagenicity]; H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure]; H371: May cause damage to organs [Warning Specific target organ toxicity, single exposure]; H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]; H373: May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] Source: NITE-CMC
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P308+P316, P318, P319, P321, P405, and P501 (click each P-code to see the statement) Source: NITE-CMC
  • Signal: Warning Source: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H315: Causes skin irritation [Warning Skin corrosion/irritation]; H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H335: May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]; H401: Toxic to aquatic life [Hazardous to the aquatic environment, acute hazard] Source: Hazardous Substances Data Bank (HSDB)
  • Health Effects: Skin rashes, blood disorders and a swollen pancreas have occasionally happened in people taking the drug on a regular basis for a long time. Source: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Acetaminophen is an odorless compound with a slightly bitter taste. It is a common analgesic and antipyretic agent used for the relief of fever as well as aches and pains associated with many conditions. HUMAN EXPOSURE AND TOXICITY: Nausea, vomiting, and abdominal pain usually occur within 2-3 hours after ingestion of toxic doses of the drug. In severe poisoning, CNS stimulation, excitement, and delirium may occur initially. This may be followed by CNS depression, stupor, hypothermia, marked prostration, rapid shallow breathing, rapid weak irregular pulse, low blood pressure, and circulatory failure. When an individual has ingested a toxic dose of acetaminophen, the individual should be hospitalized for several days of observation, even if there are no apparent ill effects, because maximum liver damage and/or cardiotoxic effects usually do not become apparent until 2-4 days after ingestion of the drug. Other symptoms of acute poisoning include cerebral edema and nonspecific myocardial depression. Vascular collapse results from the relative hypoxia and from a central depressant action that occurs only with massive doses. Shock may develop if vasodilation is m Source: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Each year, approximately 500 fatalities and 50,000 emergency department admissions in the United States are linked to acetaminophen. In 2021, US poison control centers recorded over 80,000 cases. Acetaminophen is the most prevalent drug-related cause of acute liver failure, with hepatic injury occurring as a consequence of the drug's metabolism properties. After reaching therapeutic concentrations of oral acetaminophen, 60% to 90% of the drug undergoes metabolism in the liver, forming glucuronic acid- and sulfate-conjugate metabolites. A smaller fraction, approximately 5% to 15%, undergoes metabolism via the cytochrome P450 system (CYP450)—metabolism primarily through CYP2E1 results in the formation of the toxic intermediate NAPQI.; Under normal circumstances, NAPQI is neutralized by glutathione to form nontoxic metabolites. However, in the case of excessive doses of acetaminophen, the normal phase II drug metabolism pathways become depleted. The CYP450 pathway metabolizes a more significant portion of the acetaminophen, leading to elevated concentrations of NAPQI formation, and the limited glutathione stores can deplete. When there is a shortage of glutathione, NAPQI concentration Source: StatPearls
  • Toxicity Summary: Paracetamol toxicity is one of the most common causes of poisoning worldwide. The toxic effects of acetaminophen are due to a minor alkylating metabolite (N-acetyl-p-benzo-quinone imine – also known as NAPQI), not acetaminophen itself nor any of the other major metabolites. Cytochromes P450 2E1 and 3A4 convert approximately 5% of paracetamol to NAPQI. This toxic metabolite reacts with sulfhydryl groups on proteins and with glutathione (GSH). NAPQI depletes the liver's natural antioxidant glutathione and directly damages cells in the liver, leading to liver failure. In animal studies, hepatic glutathione must be depleted to less than 70% of normal levels before hepatotoxicity occurs. More specifically, oxidation by NAPQI of GSH to GSSG (oxidized glutathione) and the reduction of GSSG back to GSH by the NADPH-dependent glutathione reductase appear to be responsible for the rapid oxidation of NADPH that occurs in hepatocytes incubated with NAPQI. Risk factors for toxicity include excessive chronic alcohol intake, fasting or anorexia nervosa, and the use of certain drugs such as isoniazid. At usual doses, paracetamol is quickly detoxified by combining irreversibly with the sulfhydryl g Source: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3 was calculated in fish for acetaminophen(SRC), using a log Kow of 0.46(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 21(SRC), determined from a log Kow of 0.46(2) and a regression-derived equation(3), indicates that acetaminophen is expected to have very high mobility in soil(SRC). Volatilization of acetaminophen from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 8.9X10-10 atm-cu m/mole(SRC), derived from its vapor pressure, 6.29X10-5 mm Hg(4), and water solubility, 1.4X10+4 mg/L(5). Acetaminophen is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(4). The biodegradation half-lives for non-adapted, phenol-adapted, and cresol-adapted activated sludge were 21, 40, and 13 days(6), respectively, suggesting that biodegradation may be an important environmental fate process in soil given acclimation(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 21(SRC), determined from a log Kow of 0.46(2) and a regression-derived equation(3), indicates that acetaminophen is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(4) based upon an estimated Henry's Law constant of 8.9X10-10 atm-cu m/mole(SRC), derived from its vapor pressure, 6.29X10-5 mm Hg(5), and water solubility, 1.4X10+4 mg/L(6). According to a classification scheme(7), an estimated BCF of 3(SRC), from its log Kow(2) and a regression-derived equation(3), suggests the potential for bioconcentration in aquatic organisms is low(SRC). The biodegradation half-lives for non-adapted, phenol-adapted, and cresol-adapted activated sludge were 21, 40, and 13 days(8), respectively, suggesting that biodegradation may be an important environmental fate process in water given acclimation(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), acetaminophen, which has an estimated vapor pressure of 6.3X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase acetaminophen is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 22 hrs(SRC), calculated from its rate constant of 1.8X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase acetaminophen may be removed from the air by wet and dry deposition(SRC). Acetaminophen absorbs light at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Sources/Uses: Registered for use in the US for control of brown tree snakes; [NPIRS] Used to make azo dyes, photographic chemicals, and pharmaceuticals, as a stabilizer for hydrogen peroxide, and as a therapeutic analgesic and antipyretic; [HSDB] Source: Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
  • Uses: Manufacture of azo dyes, photographic chemicals. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Stabilizer for hydrogen peroxide Source: Hazardous Substances Data Bank (HSDB)
  • Uses: An analgesic used as an aspirin substitute Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Analgesics, Non-Narcotic; Antipyretics Source: Hazardous Substances Data Bank (HSDB)
  • Uses: For more Uses (Complete) data for ACETAMINOPHEN (6 total), please visit the HSDB record page. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg) in Switzerland (2009): >100000; Use (kg; approx.) in Germany (2009): >500000; Use (kg; exact) in Germany (2009): 564712; Use (kg) in USA (2002): 5790000; Use (kg) in France (2004): 3303077; Consumption (g per capita) in Switzerland (2009): 13; Consumption (g per capita; approx.) in Germany (2009): 6.1; Consumption (g per capita; exact) in Germany (2009): 6.9; Consumption (g per capita) in the USA (2002): 21; Consumption (g per capita) in France (2004): 55; Excretion rate: 0.037; Calculated removal (%): 75.1 Source: NORMAN Suspect List Exchange
  • Uses: An over-the-counter analgesic (pain reliever) and antipyretic (fever reducer). It is commonly used for the relief of fever, headaches, and other minor aches and pains, and is a major ingredient in numerous cold and flu remedies. Source: Toxin and Toxin Target Database (T3DB)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
EMBL-EBI ChEBIExact match2026-08-31
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity

US EPA CompTox CTX APIs

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity

Continue the compliance check

1. Confirm identity

Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.

2. Review restrictions

Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.

3. Verify the formula

Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.

Screen in a formulaOpen standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision